Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort

Although much of the basic immunological work has been done with mice, little is known about anti-IgG autoantibodies in this species. Dresser (1, 2) has reported the occurrence, in CBA mice, of anti-IgG antibody (Ab)(1) detected by a hemolytic-plaque assay after stimulation with endotoxin or immunization against sheep erythrocytes. IgM rheumatoid factor has also been described in various strains of mice with a systemic lupus erythematosus-like disease (3). Recently, we have tried to induce anti-IgG in mice of the 129/Sv strain by inoculating autologous IgG. To our surprise, we found that the sera of all the animals had, before any inoculation, anti-IgG detectable by agglutination of particles coated with autologous IgG. The possibilities to investigate the mechanism of production and the biological role of this kind of Ab prompted us to undertake a study of the nature and specificity of the mouse anti-IgG.

Download Full-text

Humoral Immunity to Varicella Zoster Virus in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis Compared to Healthy Controls

Vaccines ◽

10.3390/vaccines9040325 ◽

2021 ◽

Vol 9 (4) ◽

pp. 325

Author(s):

Marco Krasselt ◽

Christoph Baerwald ◽

Uwe G. Liebert ◽

Olga Seifert

Keyword(s):

Rheumatoid Arthritis ◽

Systemic Lupus Erythematosus ◽

Humoral Immunity ◽

Lupus Erythematosus ◽

Antibody Concentration ◽

Healthy Controls ◽

Systemic Lupus ◽

Igg Antibody ◽

Varicella Zoster ◽

Antibody Levels

Background: The prevalence of herpes zoster (HZ) is high in patients with rheumatic diseases. Systemic lupus erythematosus (SLE) doubles the risk for developing HZ. However, little is known about natural humoral immunity against varicella zoster virus (VZV) in patients with SLE. Hence, we compared VZV IgG antibody concentrations in a group of SLE patients with healthy controls and patients with rheumatoid arthritis (RA). Methods: n = 56 patients with SLE, n = 54 patients with RA, and n = 56 healthy controls were included in this study. The VZV IgG antibody concentration was measured using an enzyme-linked immunosorbent assay (ELISA). The antibody concentrations were compared between the groups. Results: Overall IgG antibody titers for VZV in SLE patients were comparable to healthy controls but higher when compared to patients with rheumatoid arthritis (p = 0.0012). In consequence, antibody levels in controls were higher than in RA patients (p = 0.0097). Stratification by age revealed highest titers among SLE patients in the fourth life decade (p = 0.03 for controls, p = 0.0008 for RA patients) whereas RA patients in their sixth decade had the lowest antibody concentration (p = 0.03 for controls, p = 0.04 for SLE patients). Regarding the individual HZ history, antibody levels of SLE patients with a positive history exceeded all other groups. Conclusions: Although humoral VZV immunity in SLE patients is comparable to healthy controls it seems to be pronounced in young SLE patients between 30 and 39. The lowest VZV IgG levels were found in RA patients. HZ seems to induce antibody production, particularly in patients with SLE. Immunological processes might contribute to VZV antibody levels in SLE patients, but further investigations are needed to substantiate this hypothesis. Even though the increased HZ prevalence seems to be independent of humoral immunity in SLE patients, reduced humoral immunity might contribute to HZ in RA patients. The available HZ subunit vaccination might be an appropriate way to reduce the HZ risk in patients with rheumatic diseases.

Download Full-text

Longitudinal Immunoblotting Variations of Auto-Antibody Reactivity of Patients with Systemic Lupus Erythematosus

Autoimmunity ◽

10.3109/08916939009041047 ◽

1990 ◽

Vol 7 (1) ◽

pp. 23-31 ◽

Cited By ~ 2

Author(s):

O. Meyer ◽

A. Aeschlimann ◽

P. Bourgeois ◽

M. F. Kahn

Keyword(s):

Systemic Lupus Erythematosus ◽

Lupus Erythematosus ◽

Systemic Lupus ◽

Antibody Reactivity ◽

Auto Antibody

Download Full-text

Aquaporin-4 IgG antibody-related disorders in patients with juvenile systemic lupus erythematosus

Lupus ◽

10.1177/0961203319855125 ◽

2019 ◽

Vol 28 (10) ◽

pp. 1243-1249

Author(s):

E Moraitis ◽

Y Stathopoulos ◽

Y Hong ◽

M Al-Obaidi ◽

K Mankad ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Lupus Erythematosus ◽

Transverse Myelitis ◽

Aquaporin 4 ◽

Neurological Involvement ◽

Clinical Predictors ◽

Systemic Lupus ◽

Igg Antibody ◽

Juvenile Systemic Lupus Erythematosus ◽

Exact Test

Objective The aim of this study was to: (a) screen a large group of unselected patients with juvenile systemic lupus erythematosus for anti-aquaporin 4 antibodies (AQP4-Ab); (b) identify clinical and laboratory predictors of the presence of AQP4-Ab positivity in juvenile systemic lupus erythematosus. Methods Sera from 90 patients with juvenile systemic lupus erythematosus were tested for the presence of AQP4-Ab using a cell-based assay. Demographics, clinical and immunological features, treatment received were summarized. Fisher’s exact test was used to identify clinical predictors of positivity for AQP4-Ab. Results Five of 90 (5.5%) patients tested positive for AQP4-Ab, all of which had neurological involvement, mainly transverse myelitis and optic neuritis. AQP4-Ab-positive patients were more likely to have neurological symptoms ( P = 0.002), less likely to experience dermatological manifestations ( P = 0.045), and less likely to have detectable anti-dsDNA antibodies ( P = 0.022). These patients were also more likely to have received anti-epileptic ( P = 0.023) and anti-coagulant ( P = 0.007) drugs. Conclusions The findings of this study indicate that some patients with juvenile systemic lupus erythematosus develop antibodies against aquaporin-4 and may be at risk of developing a neurological clinical phenotype. We suggest that all juvenile systemic lupus erythematosus patients should be systematically screened for the presence of AQP4-Ab and this may help identify a high risk for neurological involvement in juvenile systemic lupus erythematosus.

Download Full-text